{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:11Z","timestamp":1787010131906,"version":"build-2736575974"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>High-grade gliomas (HGGs) are a rapidly progressive and highly recurrent group of primary brain tumors. Despite aggressive surgical resection with chemoradiotherapy, prognoses remained poor. Valproic acid (VPA), a histone deacetylase inhibitor has shown the potential to inhibit glioma cell growth in vitro through several diverse mechanisms. However clinical studies regarding the effect of VPA on HGGs are limited. This study aimed to investigate whether using VPA in patients with HGGs under temozolomide (TMZ) would lead to a better overall survival (OS).<\/jats:p>\n                    <jats:p>We used the Taiwan National Health Insurance Research database to conduct this population-based cohort study. A total of 2379 patients with HGGs under TMZ treatment were included and were further classified into VPA (n\u200a=\u200a1212, VPA \u2265 84 defined daily dose [DDD]) and non-VPA (n\u200a=\u200a1167, VPA &lt; 84 DDD) groups. Each patient was followed from 1998 to 2013 or until death. A Cox proportional hazard regression was performed to evaluate the effect of VPA and OS.<\/jats:p>\n                    <jats:p>\n                      The VPA group had a longer mean OS time compared with the non-VPA group (OS: 50.3\u200a\u00b1\u200a41.0 vs 42.0\u200a\u00b1\u200a37.2 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.001). In patients between 18 and 40 years old, the difference is most significant (OS: 70.5\u200a\u00b1\u200a48.7 vs 55.1\u200a\u00b1\u200a46.0,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.001). The adjusted hazard ratio is 0.81 (95% confidence interval, 0.72\u20130.91) for the VPA group relative to the non-VPA group.\n                    <\/jats:p>\n                    <jats:p>VPA at over 84 DDD improved OS in HGGs TMZ treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000021147","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T05:05:41Z","timestamp":1594271141000},"page":"e21147","source":"Crossref","is-referenced-by-count":19,"title":["Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide"],"prefix":"10.1097","volume":"99","author":[{"given":"Yu-Jen","family":"Kuo","sequence":"first","affiliation":[{"name":"Department of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Hsu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital"},{"name":"Health Information and Epidemiology Laboratory of Chang Gung Memorial Hospital, Chiayi"},{"name":"School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Yun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau-Chung","family":"Chen","sequence":"additional","affiliation":[{"name":"Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health, Taipei"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Tsung","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery"},{"name":"Chang Gung University, College of Medicine, Taoyuan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Chung","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Hsiu-Chu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hsun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Tai","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chao","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hsueh","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery"},{"name":"Chang Gung University of Science and Technology Chiayi Campus, Chiayi, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"e0129602","DOI":"10.1371\/journal.pone.0129602","article-title":"International differences in treatment and clinical outcomes for high grade glioma","volume":"10","author":"Chien","year":"2015","journal-title":"PLoS One"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11060-017-2607-5","article-title":"Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish neuro-oncology registry","volume":"135","author":"Rasmussen","year":"2017","journal-title":"J Neurooncol"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1007\/s00415-018-8857-0","article-title":"Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study","volume":"265","author":"Berntsson","year":"2018","journal-title":"J Neurol"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/neuonc\/nou356","article-title":"Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study","volume":"17","author":"Nabors","year":"2015","journal-title":"Neuro Oncol"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ijc.20774","article-title":"Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid","volume":"114","author":"Camphausen","year":"2005","journal-title":"Int J Cancer"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1111\/j.1582-4934.2011.01296.x","article-title":"Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic","volume":"15","author":"Shabason","year":"2011","journal-title":"J Cell Mol Med"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1038\/onc.2011.614","article-title":"Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP","volume":"31","author":"Bangert","year":"2012","journal-title":"Oncogene"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1158\/1078-0432.CCR-08-0643","article-title":"Postradiation sensitization of the histone deacetylase inhibitor valproic acid","volume":"14","author":"Chinnaiyan","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","article-title":"Valproic acid induces p21 and topoisomerase-II (alpha\/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines","volume":"85","author":"Das","year":"2007","journal-title":"J Neurooncol"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","article-title":"A Phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma","volume":"92","author":"Krauze","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/neuonc\/not057","article-title":"Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme","volume":"15","author":"Kerkhof","year":"2013","journal-title":"Neuro Oncol"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijrobp.2013.02.012","article-title":"Valproic acid use during radiation therapy for glioblastoma associated with improved survival","volume":"86","author":"Barker","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","article-title":"Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma","volume":"77","author":"Weller","year":"2011","journal-title":"Neurology"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-016-2167-1","article-title":"Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma","volume":"73","author":"Watanabe","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/lary.26789","article-title":"Sleep apnea and risk of vertigo: a nationwide population-based cohort study","volume":"128","author":"Tsai","year":"2018","journal-title":"Laryngoscope"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bj.2017.08.002","article-title":"Chang Gung Research Database: a multi-institutional database consisting of original medical records","volume":"40","author":"Tsai","year":"2017","journal-title":"Biomed J"},{"key":"R21-20230915","first-page":"3585","article-title":"Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro","volume":"18","author":"Knupfer","year":"1998","journal-title":"Anticancer Res"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2176\/nmc.52.186","article-title":"Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain","volume":"52","author":"Osuka","year":"2012","journal-title":"Neurol Med Chir"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"14666","DOI":"10.18632\/oncotarget.14716","article-title":"Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression","volume":"8","author":"Tseng","year":"2017","journal-title":"Oncotarget"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J Biol Chem"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00109-010-0707-1","article-title":"Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation","volume":"89","author":"Chen","year":"2011","journal-title":"J Mol Med (Berl)"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tranon.2016.12.011","article-title":"Dual functional mesoporous silicon nanoparticles enhance the radiosensitivity of VPA in glioblastoma","volume":"10","author":"Zhang","year":"2017","journal-title":"Transl Oncol"},{"key":"R27-20230915","first-page":"263","article-title":"The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells","volume":"122","author":"Hosein","year":"2015","journal-title":"Transl Oncol"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4143\/crt.2014.026","article-title":"In vitro and in vivo radiosensitizing effect of valproic acid on fractionated irradiation","volume":"47","author":"Chie","year":"2015","journal-title":"Cancer Res Treat"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1159\/000447912","article-title":"Valproic acid promotes human glioma U87 cells apoptosis and inhibits glycogen synthase kinase-3beta through ERK\/AKT signaling","volume":"39","author":"Zhang","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-011-0725-z","article-title":"Valproic acid sensitizes human glioma cells for temozolomide and gamma-radiation","volume":"107","author":"Van Nifterik","year":"2012","journal-title":"J Neurooncol"},{"key":"R31-20230915","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/987495","article-title":"Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells","volume":"2012","author":"Ryu","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"62989","DOI":"10.18632\/oncotarget.11379","article-title":"Molecular dissection of the valproic acid effects on glioma cells","volume":"7","author":"Hoja","year":"2016","journal-title":"Oncotarget"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"35004","DOI":"10.18632\/oncotarget.5253","article-title":"Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells","volume":"6","author":"Thotala","year":"2015","journal-title":"Oncotarget"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1038\/onc.2017.112","article-title":"Bone morphogenetic protein signaling mediated by ALK-2 and DLX2 regulates apoptosis in glioma-initiating cells","volume":"36","author":"Raja","year":"2017","journal-title":"Oncogene"},{"key":"R35-20230915","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.3892\/or.2016.4665","article-title":"Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity","volume":"35","author":"Riva","year":"2016","journal-title":"Oncol Rep"},{"key":"R36-20230915","doi-asserted-by":"crossref","first-page":"21424","DOI":"10.1074\/jbc.M116.751503","article-title":"Induction of glycosphingolipid GM3 expression by valproic acid suppresses cancer cell growth","volume":"291","author":"Kawashima","year":"2016","journal-title":"J Biol Chem"},{"key":"R37-20230915","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0959-8049(97)00374-2","article-title":"Prevalence and prognostic significance of epilepsy in patients with gliomas","volume":"34","author":"Lote","year":"1998","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"R38-20230915","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1474-4422(07)70103-5","article-title":"Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management","volume":"6","author":"van Breemen","year":"2007","journal-title":"Lancet Neurol"},{"key":"R39-20230915","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/cncr.21221","article-title":"The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years","volume":"104","author":"Korshunov","year":"2005","journal-title":"Cancer"},{"key":"R40-20230915","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/sdi.12385","article-title":"Use of antiepileptic drugs in patients with chronic kidney disease and end stage renal disease","volume":"28","author":"Bansal","year":"2015","journal-title":"Semin Dial"},{"key":"R41-20230915","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1528-1167.2011.03316.x","article-title":"Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis","volume":"53","author":"Chuang","year":"2012","journal-title":"Epilepsia"},{"key":"R42-20230915","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.seizure.2014.05.011","article-title":"The effects of antiepileptic drugs on vascular risk factors: a narrative review","volume":"23","author":"Katsiki","year":"2014","journal-title":"Seizure"},{"key":"R43-20230915","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1136\/jnnp.54.10.915","article-title":"The prognosis of primary intracerebral tumours presenting with epilepsy: the outcome of medical and surgical management","volume":"54","author":"Smith","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R44-20230915","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2","article-title":"Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study","volume":"52","author":"Chang","year":"1983","journal-title":"Cancer"},{"key":"R45-20230915","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.3171\/2014.9.FOCUS14516","article-title":"Bevacizumab for glioblastoma: current indications, surgical implications, and future directions","volume":"37","author":"Castro","year":"2014","journal-title":"Neurosurg Focus"},{"key":"R46-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00282","article-title":"Prolonged partial response to bevacizumab and valproic acid in a patient with glioblastoma","volume":"2","author":"Fountzilas","year":"2018","journal-title":"JCO Precis Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T12:13:30Z","timestamp":1723205610000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021147"}},"subtitle":["A nationwide population-based cohort study in Taiwan"],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":46,"journal-issue":{"issue":"28","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021147","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]}}}